PET/CT measures ENDO-HDR response, may let patients skip chemo

01/30/2013 | AuntMinnie.com (free registration)

PET/CT imaging can determine pathological response in postsurgery patients with stage II and III rectal cancer who underwent short high-dose-rate endorectal brachytherapy prior to surgery, according to results presented at a gastrointestinal cancers meeting. ENDO-HDR may allow patients to avoid chemotherapy before surgery, researchers said. They also hope the method will allow for nonoperative management of many patients.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA